Moderna, Inc. $MRNA Stock: New York Life Investment Management LLC Reduces Holdings

New York Life Investment Management LLC trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 44.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 50,938 shares of the company’s stock after selling 40,297 shares during the period. New York Life Investment Management LLC’s holdings in Moderna were worth $9,809,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in Moderna during the second quarter valued at about $2,142,877,000. Theleme Partners LLP acquired a new stake in Moderna during the second quarter worth about $564,272,000. Wellington Management Group LLP raised its holdings in shares of Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after purchasing an additional 103,977 shares during the period. Merck & Co. Inc. purchased a new position in shares of Moderna in the 2nd quarter worth about $161,642,545. Finally, Bamco Inc. NY purchased a new position in shares of Moderna in the 2nd quarter worth about $139,317,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on MRNA shares. Argus upgraded Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Friday, August 28th. Rothschild & Co Redburn lowered shares of Moderna from a “neutral” rating to a “sell” rating and raised their price target for the company from $40.00 to $81.00 in a report on Thursday, September 3rd. Morgan Stanley raised their price target on shares of Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Finally, Loop Capital set a $135.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $113.75.

Key Headlines Impacting Moderna

Here are a few of the latest headlines about MRNA:

• Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year and above estimates, and beat the consensus EPS forecast. The company also raised its full-year revenue-growth outlook, providing the clearest near-term catalyst for the recent share strength. Why is Moderna stock soaring today
• Positive Sentiment: A publication in JAMA Network Open reported real-world comparative effectiveness data for mNEXSPIKE in adults aged 65 and older, based on more than 294,000 U.S. veterans. The findings could support the vaccine’s value in an important older-adult population. mNEXSPIKE real-world effectiveness publication
• Neutral Sentiment: Brookline Capital Markets kept a Buy rating and raised its 2026–2028 EPS estimates, although it still projects losses in those years. Moderna analyst estimate revisions

Insider Activity

In related news, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by corporate insiders.

Moderna Stock Down 0.9%

Shares of NASDAQ MRNA opened at $248.69 on Thursday. The stock has a fifty day moving average price of $198.57 and a 200 day moving average price of $94.60. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $280.80. The company has a market cap of $100.63 billion, a P/E ratio of -35.03 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. The firm’s quarterly revenue was up 29.2% on a year-over-year basis. Research analysts anticipate that Moderna, Inc. will post -5.34 EPS for the current fiscal year.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.